Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Stanford University |
---|---|
Information provided by: | Stanford University |
ClinicalTrials.gov Identifier: | NCT00185848 |
The purpose of this study is to determine whether [18F]FHBG is suitable for use as an imaging probe in cancer or rheumatoid arthritis patients enrolled in gene therapy trials. In this phase 1 study we will assess the safety and biodistribution of [18F]FHBG in patients.
Condition |
---|
Central Nervous System Neoplasms Brain Cancer Glioma Arthritis, Rheumatoid |
Study Type: | Observational |
Study Design: | Prospective |
Official Title: | Imaging the Biodistribution of the Positron Emission Tomography Reporter Probe, [18F]FHBG, in Humans. |
Estimated Enrollment: | 10 |
Study Start Date: | April 2005 |
The success of gene therapy depends on specific targeting of the therapeutic gene that is administered to the patient. Our goal is to develop an imaging method to non-invasively monitor the location of the therapeutic gene. Imaging should help in the design of better protocols and potentially reduce side-effects of gene therapy.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:- Clinical diagnosis of brain tumor or rheumatoid arthritis
 Exclusion Criteria:- Below 18 years of age
United States, California | |
Stanford University School of Medicine | Recruiting |
Stanford, California, United States, 94305 | |
Contact: Shahriar Shah Yaghoubi 650-736-9822 syaghoub@stanford.edu | |
Contact: Lindee Burton (650) 721-2024 lburton@stanford.edu | |
Principal Investigator: Sanjiv Sam Gambhir M.D., Ph.D. | |
Sub-Investigator: Michael L Goris | |
Sub-Investigator: Dr Andrew Quon | |
Sub-Investigator: Dr Lawrence Recht | |
Sub-Investigator: Shahriar Shah Yaghoubi |
Principal Investigator: | Sanjiv Sam Gambhir M.D., Ph.D. | Stanford University |
Study ID Numbers: | BRNCNS0003, 95908, BRNCNS0003, NCT00185848 |
Study First Received: | September 12, 2005 |
Last Updated: | December 2, 2008 |
ClinicalTrials.gov Identifier: | NCT00185848 |
Health Authority: | United States: Food and Drug Administration; United States: Institutional Review Board |
Autoimmune Diseases Joint Diseases Arthritis, Rheumatoid Central Nervous System Diseases Central Nervous System Neoplasms Rheumatic Diseases Brain Diseases |
Brain Neoplasms Musculoskeletal Diseases Arthritis Connective Tissue Diseases Glioma Nervous System Neoplasms |
Neoplasms Neoplasms by Site Immune System Diseases Nervous System Diseases |